Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of GBP 16.89 billion. The enterprise value is 20.91 billion.

Market Cap	16.89B
Enterprise Value	20.91B

Important Dates

The next estimated earnings date is Thursday, February 13, 2025.

Earnings Date	Feb 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.34%
Shares Change (QoQ)	+0.14%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.23M

Valuation Ratios

The trailing PE ratio is 14.02.

PE Ratio	14.02
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	334.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.42, with an EV/FCF ratio of 14.39.

EV / Earnings	17.35
EV / Sales	2.68
EV / EBITDA	8.42
EV / EBIT	11.42
EV / FCF	14.39

Financial Position

The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.41.

Current Ratio	1.26
Quick Ratio	0.68
Debt / Equity	0.41
Debt / EBITDA	2.17
Debt / FCF	3.42
Interest Coverage	8.62

Financial Efficiency

Return on equity (ROE) is 10.47% and return on invested capital (ROIC) is 6.24%.

Return on Equity (ROE)	10.47%
Return on Assets (ROA)	4.99%
Return on Capital (ROIC)	6.24%
Revenue Per Employee	946,916
Profits Per Employee	159,194
Employee Count	7,570
Asset Turnover	0.34
Inventory Turnover	0.86

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.00% in the last 52 weeks. The beta is -0.06, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	-0.06
52-Week Price Change	-43.00%
50-Day Moving Average	154.97
200-Day Moving Average	194.81
Relative Strength Index (RSI)	33.31
Average Volume (20 Days)	3,533

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.41

Income Statement

In the last 12 months, Biogen had revenue of GBP 7.17 billion and earned 1.21 billion in profits. Earnings per share was 8.25.

Revenue	7.17B
Gross Profit	5.42B
Operating Income	1.68B
Pretax Income	1.42B
Net Income	1.21B
EBITDA	2.15B
EBIT	1.68B
Earnings Per Share (EPS)	8.25

Full Income Statement

Balance Sheet

The company has 1.27 billion in cash and 4.96 billion in debt, giving a net cash position of -3.69 billion.

Cash & Cash Equivalents	1.27B
Total Debt	4.96B
Net Cash	-3.69B
Net Cash Per Share	n/a
Equity (Book Value)	12.21B
Book Value Per Share	83.77
Working Capital	1.05B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.59 billion and capital expenditures -134.00 million, giving a free cash flow of 1.45 billion.

Operating Cash Flow	1.59B
Capital Expenditures	-134.00M
Free Cash Flow	1.45B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 75.59%, with operating and profit margins of 23.48% and 16.81%.

Gross Margin	75.59%
Operating Margin	23.48%
Pretax Margin	19.84%
Profit Margin	16.81%
EBITDA Margin	30.03%
EBIT Margin	23.48%
FCF Margin	20.27%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.34%
Shareholder Yield	-0.34%
Earnings Yield	7.14%
FCF Yield	8.60%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 3.25.

Altman Z-Score	3.25
Piotroski F-Score	n/a